Oncotelic presents Phase 1/2 OT-101 pancreatic cancer data; median OS doubled in patients receiving subsequent chemo

Oncotelic Therapeutics, Inc.

55% of OT-101-treated pancreatic cancer patients had long-term disease control (21 of 37 pts).
Median OS doubled to 9.3 vs 2.6 months (p<0.0001) for those who received subsequent chemotherapy.
High AUC associated with improved OS: 9.6 vs 2.4 months (p=0.0006).
OT-101 PK dose proportional (p<0.0001).
Presentation from JCA-AACR conference available on company website and YouTube.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.